Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human papillomavirus type 6 L1 capsid protein antigen
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Human papillomavirus type 6 L1 capsid protein antigen is a recombinant viral protein used as an active component in prophylactic vaccines against human papillomavirus (HPV), such as Gardasil and Gardasil 9. The antigen is the major capsid (L1) protein of HPV type 6, produced using recombinant DNA technology in yeast (*Saccharomyces cerevisiae*) or *E. coli*. The purified L1 proteins self-assemble into noninfectious virus-like particles (VLPs) that mimic the structure of native virions but lack viral DNA. These VLPs elicit a strong immune response by inducing neutralizing antibodies against HPV, thereby preventing infection and associated diseases such as genital warts and cervical cancer precursors caused by vaccine-included types[1][5][4]. The primary indication is immunization for prevention of diseases caused by specific HPV types.
- Brand names
- GardasilGardasil 9Gardasil9Gardasil-9
- Other names
- HPV type 6 L1 capsid protein antigenHPV6 L1 VLPHPV-6 L1 VLPHPV 6 L1 VLPrecombinant HPV type 6 L1 protein
02
Targets
BCR (Immunoglobulin G B Cell Receptor)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on Human papillomavirus type 6 L1 capsid protein antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human papillomavirus type 6 L1 capsid protein antigen.